HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Medulloblastoma — Clinical Guidelines

Overview

Medulloblastoma is an aggressive, undifferentiated brain tumor primarily occurring in the posterior fossa, predominantly affecting children but also seen in adults. Recent molecular profiling has reclassified medulloblastoma into distinct subgroups with varying prognoses and treatment sensitivities 3 5 6.

Diagnosis

Radiological Evaluation: Initial diagnosis often involves radiological imaging (e.g., MRI) showing characteristic features of a posterior fossa mass 3.

Surgical Resection: Maximum safe resection followed by post-surgical MRI within 48 hours to assess residual tumor 3.

Histopathological Confirmation: Essential for definitive diagnosis; histological examination identifies specific tumor characteristics 9.

Molecular Profiling: Recommended for risk stratification and guiding treatment decisions 3 5 6.

Leptomeningeal Metastasis Assessment: Consider cerebrospinal fluid analysis and imaging for leptomeningeal spread 7.

Blood Brain Barrier Integrity: Assessed via imaging or biomarkers, particularly relevant for treatment planning 8.

Management

Primary Treatment: Surgical resection followed by adjuvant radiotherapy and chemotherapy tailored to molecular subgroup 3 5.

Adjunctive Therapies:

- Chemotherapy: Varies based on risk stratification; specific regimens not detailed in abstracts 3 5. - Ketamine: Considered for severe leptomeningeal pain refractory to opioids 2. - Percutaneous Cordotomy: Effective for managing severe cancer pain in pediatric patients 10.

Targeted Therapies: Emerging based on molecular subgroups; specific drugs not detailed in abstracts 5 6.

Special Populations

Pediatrics: Management heavily influenced by molecular profiling for risk stratification and tailored therapy 3 5.

Recurrent Disease: Histological confirmation crucial to avoid misdiagnosis; treatment options include re-resection, radiotherapy, and chemotherapy 9.

Key Recommendations

Perform maximum safe surgical resection followed by post-surgical imaging and molecular profiling for accurate risk stratification and treatment planning (Evidence: Strong 3 5 6).

Incorporate molecular subgroup analysis to guide adjuvant therapies, recognizing that treatment sensitivity varies significantly across subgroups (Evidence: Strong 5 6).

Utilize ketamine as an adjunct to opioids for managing severe leptomeningeal pain in terminally ill patients (Evidence: Moderate 2).

Ensure histological confirmation in suspected recurrent medulloblastoma to avoid misdiagnosis and inappropriate treatment escalation (Evidence: Expert opinion 9).

References

1 . A Transitional Cell Population Is Enriched in Aggressive Human Medulloblastoma. Cancer discovery 2023. link 2 Tam YS, Chen E, Poh ZE, Chia G, Provido M, Hum A et al.. Ketamine in Severe Leptomeningeal Pain. Journal of palliative medicine 2023. link 3 Luque R, Benavides M, Del Barco S, Egaña L, García-Gómez J, Martínez-García M et al.. SEOM clinical guideline for management of adult medulloblastoma (2020). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021. link 4 . Granule Neuron Precursor-Derived Astrocytes Promote Medulloblastoma. Cancer discovery 2020. link 5 Park AK, Lee JY, Cheong H, Ramaswamy V, Park SH, Kool M et al.. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. BMC cancer 2019. link 6 . Study Reveals Germline Genetics of Medulloblastoma. Cancer discovery 2018. link 7 . Medulloblastoma Circulating Tumor Cells Form Leptomeningeal Metastases. Cancer discovery 2018. link 8 . Blood Brain Barrier Phenotype Is Determined by Medulloblastoma Subtype. Cancer discovery 2016. link 9 Weintraub L, Miller T, Friedman I, Abbott R, Levy AS. Misdiagnosing recurrent medulloblastoma: the danger of examination and imaging without histological confirmation. Journal of neurosurgery. Pediatrics 2014. link 10 Reddy GD, Okhuysen-Cawley R, Harsh V, Viswanathan A. Percutaneous CT-guided cordotomy for the treatment of pediatric cancer pain. Journal of neurosurgery. Pediatrics 2013. link 11 Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ et al.. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004. link 12 Manshande JP, Van Tornout J, Coppens M, Casaer P. Seasonal variation in incidence of cerebellar medulloblastoma. Brain & development 1985. link80124-8) 13 Kumanishi T, Washiyama K, Watabe K, Sekiguchi K. Glial fibrillary acidic protein in medulloblastomas. Acta neuropathologica 1985. link 14 Duinkerke SJ, Slooff JL, Gabreëls FJ, Renier WO, Thijssen HO, Biesta JH. Melanotic rhabdomyomedulloblastoma or teratoid tumour of the cerebellar vermis. Clinical neurology and neurosurgery 1981. link80006-6) 15 Parkinson D, Ross RT, Shields CB. Metastatic medulloblastoma. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1974. link

Medulloblastoma